Back to search results

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Abroad (travel likely)RecruitingPHASE2

Conditions

Glioblastoma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Glioma · Brain Neoplasm · Brain Cancer · Brain Tumor · Brain Tumor, Recurrent · Brain Neoplasm, Malignant

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Lenox Hill Brain Tumor Center, New York, New York, United States

    Contact: Study coordinator (John Boockvar, MD) · jboockvar@northwell.edu · 212-434-3900
    Contact: Study coordinator (Tamika Wong, MPH) · twong4@northwell.edu · 212-434-4836
    Contact: Principal Investigator (John Boockvar, MD)
    David Langer, MD (Sub-investigator)
    Rafael Ortiz, MD (Sub-investigator)
    Alexis Demopoulos, MD (Sub-investigator)
    Jed Pollack, MD (Sub-investigator)
    Anuj Goenka, MD (Sub-investigator)
    Sherese Fralin, NP (Sub-investigator)
    Ashley Ray, NP (Sub-investigator)
    Karissa Tan, NP (Sub-investigator)
    Tamika Wong, MPH (Sub-investigator)
Study leads

  • John Boockvar, MD

    Principal Investigator

    Northwell Health

View source on ClinicalTrials.gov(opens in a new tab)